Tolerance to nitrates with enhanced radical formation suppressed by carvedilol.
Enhanced oxidant stress occurs under many pathophysiologic conditions (e.g., inflammation) and can be induced and mimicked by continuous nitrate therapy, eliciting increases in platelet activity, enhanced formation of reactive oxygen species (ROS), and impaired nitrate-induced vasorelaxation. Analysis was performed of effects of coinfusion of glycerol trinitrate (GTN) either with a carvedilol metabolite with antioxidant properties or with antioxidant vitamin C (Vit-C) on various hemodynamic parameters during enhanced oxidant stress associated with nitrate tolerance. Carvedilol metabolite (BM910228: 4.5 microg/kg/min) or Vit-C (55 microg/kg/min) was coadministered with GTN (1.5 microg/kg/min) for 5 days in chronically instrumented dogs. Changes in coronary diameters (CD) and other hemodynamic parameters were continuously monitored, as well as changes in platelet function. At the beginning of GTN treatment, CD increased by 9.8 +/- 0.4% and progressively declined to basal control values within 3 days. However, with additional antioxidant protection either with BM910228 or with Vit-C, the GTN-induced increase in CD was maintained (8.6 +/- 0.4% or 10.5 +/- 0.6%) and remained elevated for the entire infusion period. The thrombin-stimulated intracellular Ca2+ concentrations of platelets remained nearly unchanged during Vit-C or BM910228 in contrast to the increase with GTN. The basal cyclic guanosine monophosphate (cGMP) contents of platelets after GTN coadministered with BM910228 or with Vit-C increased on day 1 to 233 or to 250% versus control and remained at that level. Additional in vitro tests with xanthine oxidase-induced oxidant stress resulted in a more or less pronounced scavenging of O2- radicals by BM920228, Vit-C, or superoxide dismutase (SOD). Coadministration of carvedilol metabolite BM910228 or of Vit-C along with GTN suppressed noxious effects of GTN-induced oxidant stress such as increased platelet activity and impaired nitrate-induced vasorelaxation.
Fink
B
B
Institute of Applied Physiology, Albert-Ludwigs University, Freiburg, Germany. bfink@ruf.uni-freiburg.de
Schwemmer
M
M
Fink
N
N
Bassenge
E
E
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology*; D000818:Animals; D000975:Antioxidants / Q000494:pharmacology*; D001205:Ascorbic Acid / Q000494:pharmacology; D001792:Blood Platelets / Q000187:drug effects; D002118:Calcium / Q000097:blood; D002227:Carbazoles / Q000494:pharmacology*; D000077261:Carvedilol; D006152:Cyclic GMP / Q000097:blood; D004285:Dogs; D005260:Female; D008297:Male; D005996:Nitroglycerin / Q000037:antagonists & inhibitors / Q000633:toxicity*; D009599:Nitroprusside / Q000494:pharmacology; D010974:Platelet Aggregation / Q000187:drug effects; D011412:Propanolamines / Q000494:pharmacology*; D017382:Reactive Oxygen Species / Q000378:metabolism; D014665:Vasodilator Agents / Q000494:pharmacology
D000319:Adrenergic beta-Antagonists; D000975:Antioxidants; C103832:BM 910228; D002227:Carbazoles; D011412:Propanolamines; D017382:Reactive Oxygen Species; D014665:Vasodilator Agents; D000077261:Carvedilol; D009599:Nitroprusside; D005996:Nitroglycerin; D006152:Cyclic GMP; D001205:Ascorbic Acid; D002118:Calcium